Compare Stocks → Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:MBRXNASDAQ:TOCANASDAQ:TRVINASDAQ:ZFGNNASDAQ:ZSAN Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBRXMoleculin Biotech$4.65+2.9%$7.07$4.28▼$15.75$10.37M1.9530,571 shs10,562 shsTOCATocagen$0.73-6.4%$32.24$0.42▼$6.77$17.56M0.011.47 million shs8,346 shsTRVITrevi Therapeutics$2.84+5.6%$2.92$0.97▼$4.00$195.50M0.86281,369 shs144,331 shsZFGNZafgen$6.53+2.4%$18.47$0.62▼$2.76$244.68M0.27360,199 shs509,168 shsZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBRXMoleculin Biotech+6.07%-5.02%-42.22%-44.66%-62.17%TOCATocagen+5.41%+8.33%+18.18%+12.13%-26.42%TRVITrevi Therapeutics+4.07%-9.90%-22.40%+98.89%+9.15%ZFGNZafgen-9.50%-11.63%-25.73%+47.00%+29.67%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Secret Bull Market Starts in This Unusual Sector (Ad)"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch. Click for my No. 1 investment, all free of charge, click here. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMBRXMoleculin Biotech2.278 of 5 stars3.53.00.00.02.90.01.3TOCATocagenN/AN/AN/AN/AN/AN/AN/AN/ATRVITrevi Therapeutics2.4032 of 5 stars3.54.00.00.01.43.30.0ZFGNZafgenN/AN/AN/AN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBRXMoleculin Biotech3.00Buy$35.00652.69% UpsideTOCATocagenN/AN/AN/AN/ATRVITrevi Therapeutics3.00Buy$8.50199.82% UpsideZFGNZafgenN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest ZFGN, ZSAN, TRVI, MBRX, and TOCA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/12/2024MBRXMoleculin BiotechRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.004/9/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.003/26/2024MBRXMoleculin BiotechMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $20.003/21/2024TRVITrevi TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$9.003/21/2024TRVITrevi TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBRXMoleculin BiotechN/AN/AN/AN/A$11.70 per shareN/ATOCATocagen$40K438.91N/AN/A$0.45 per share1.63TRVITrevi TherapeuticsN/AN/AN/AN/A$1.29 per shareN/AZFGNZafgenN/AN/AN/AN/A$1.35 per shareN/AZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBRXMoleculin Biotech-$29.77M-$13.64N/AN/AN/AN/A-80.91%-67.69%5/9/2024 (Estimated)TOCATocagen-$63.52M-$2.69N/AN/AN/A-176,433.34%-327.74%-111.87%N/ATRVITrevi Therapeutics-$29.07M-$0.29N/AN/AN/AN/A-31.51%-28.89%5/9/2024 (Estimated)ZFGNZafgen-$45.41M-$1.07N/A∞N/AN/A-51.34%-34.55%N/AZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ALatest ZFGN, ZSAN, TRVI, MBRX, and TOCA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/20/2024Q4 2023TRVITrevi Therapeutics-$0.10-$0.08+$0.02-$0.08N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBRXMoleculin BiotechN/AN/AN/AN/AN/ATOCATocagenN/AN/AN/AN/AN/ATRVITrevi TherapeuticsN/AN/AN/AN/AN/AZFGNZafgenN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBRXMoleculin BiotechN/A3.863.86TOCATocagen1.881.151.15TRVITrevi TherapeuticsN/A15.0315.03ZFGNZafgen0.266.566.56ZSANZosano PharmaN/A1.611.61OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBRXMoleculin Biotech15.52%TOCATocagen21.42%TRVITrevi Therapeutics95.76%ZFGNZafgen70.43%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipMBRXMoleculin Biotech6.70%TOCATocagen10.90%TRVITrevi Therapeutics27.46%ZFGNZafgen14.20%ZSANZosano Pharma2.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableMBRXMoleculin Biotech182.23 million2.08 millionNot OptionableTOCATocagen7723.92 millionN/ANot OptionableTRVITrevi Therapeutics2568.96 million50.02 millionOptionableZFGNZafgen3837.47 millionN/ANot OptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableZFGN, ZSAN, TRVI, MBRX, and TOCA HeadlinesSourceHeadlineHOOK HOOKIPA Pharma Inc.seekingalpha.com - April 12 at 10:11 PMNachrichten - Weitere Nachrichtenwallstreet-online.de - January 9 at 2:39 PMLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planpbs.org - December 6 at 7:44 AMDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abn-tv.de - August 22 at 3:36 PMEast Bay Business Newsbizjournals.com - May 18 at 9:49 PMMankind Pharma IPO opens on April 25, listing scheduled for May 9moneycontrol.com - April 27 at 4:20 PMAstellas Pharmaforbes.com - April 6 at 12:00 PMGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis Foundationfinance.yahoo.com - February 5 at 12:11 PMFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by orderswashingtonexaminer.com - January 23 at 3:25 PMZosano Pharma Corporation (ZSANQ)ca.finance.yahoo.com - November 5 at 6:33 PMNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli Lillyendpts.com - October 13 at 11:22 AMBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma Giantsmsn.com - October 12 at 2:32 PMBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of Claimsmarketwatch.com - August 28 at 7:45 PMEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionbizjournals.com - August 27 at 4:10 PMZosano Pharma Corp (ZSANQ)investing.com - August 25 at 12:28 AMEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1Mbizjournals.com - July 26 at 8:27 PMA Fremont company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1M.bizjournals.com - July 26 at 8:27 PMZosano Pharma Corporation [ZSAN] stock Initiated by Maxim Group analyst, price target now $8dbtnews.com - June 3 at 11:27 AMZosano Pharma Shares Slide to New Depths After Chapter 11 Filing >ZSANmarketwatch.com - June 2 at 3:26 PMWhy Zosano Pharma Shares Are Getting Hammered Todaymsn.com - June 2 at 3:26 PMZosano Pharma files for Chapter 11 bankruptcy protection; shares plummet 46%seekingalpha.com - June 2 at 10:26 AMCash-Strapped Zosano Pharma Files for Chapter 11 Bankruptcy >ZSANmarketwatch.com - June 2 at 10:26 AMEast Bay migraine patch developer files for bankruptcybizjournals.com - June 2 at 10:26 AMZosano Pharma Files Voluntary Petition for Relief Under Chapter 11finance.yahoo.com - June 2 at 10:26 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsMoleculin BiotechNASDAQ:MBRXMoleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066 that is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It is also developing WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company was incorporated in 2015 and is headquartered in Houston, Texas.TocagenNASDAQ:TOCATocagen Inc., a clinical-stage cancer-selective gene therapy company, focuses on developing and commercializing product candidates designed to activate a patient's immune system against their cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors (RRVs), which are designed to deliver therapeutic genes into the DNA of cancer cells. The company's lead product candidate is Toca 511 & Toca FC that is under Phase III clinical trial for recurrent high-grade glioma. It is also developing Toca 511 & Toca FC in a Phase Ib clinical trial for intravenous treatment of advanced cancers. In addition, the company is developing other RRVs to deliver genes to cancer cells against validated immunotherapy targets. The company has a license agreement with ApolloBio to develop and commercialize Toca 511 & Toca FC; and a collaboration agreement with NRG Oncology to develop a clinical trial utilizing Toca 511 & Toca FC for the treatment of patients with newly diagnosed glioblastoma. Tocagen Inc. was founded in 2007 and is based in San Diego, California.Trevi TherapeuticsNASDAQ:TRVITrevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.ZafgenNASDAQ:ZFGNZafgen, Inc., a clinical-stage biopharmaceutical company, develops therapies for patients suffering from metabolic diseases comprising type 2 diabetes, Prader-Willi syndrome (PWS), and other metabolically related disorders. The company's lead product candidate is ZGN-1061, a fumagillin-class methionine aminopeptidase 2 (MetAP2) inhibitor administered by subcutaneous injection, which is in Phase 2 clinical trial and profiled for its utility in the treatment of type 2 diabetes and other related metabolic disorders. It also develops ZGN-1258, a MetAP2 inhibitor for treatment of PWS. Zafgen, Inc. was founded in 2005 and is headquartered in Boston, Massachusetts.Zosano PharmaNASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.